The quest for efficacy in pancreatic cancer
Late-stage therapies from Fibrogen, Tyme and Novartis need to avoid the same pitfalls as Erytech and Rafael.
Takeda gets the pipeline blues
A big selloff on a mid-stage stumble seems harsh, but Takeda has problems on the horizon.
Novartis pushes on with iscalimab after transplant disappointment
The autoimmune target CD40 has yielded few hits despite years of research, but a few companies are keeping the faith.
Horizon looks for a new growth driver
The company plans to make the most of its head start with the Graves’ disease project teprotumumab, which is forecast to become its biggest product.
Scholar thinks Glaxo made a wise move to back Merck
Scholar Rock selects a lead molecule inhibiting TGF-β, an increasingly important oncology mechanism that Glaxosmithkline recently paid €300m to enter.
Christmas comes early for Agenus
The struggling US biotech receives a $150m windfall from Gilead, a group desperate to make its mark in oncology.